glp-1 obesity drug news october 9 2025 GLP‑1 real‑world data for obesity: A new standard for metabolic care Outlook for obesity in 2025:

Kaku K, Yamada Y, Watada H, et al

[8] SURPASS-2 : Tirzepatide (5, 10, 15 mg) reduced HbA1c by 2.01%2.30%, compared to 1.86% with semaglutide (1 mg)

EC50 values obtained using this method were then used to calculate: sample ratio = sample EC50/EC50 reference peptide-spiked plasma sample and estimated concentration = Known top concentration of peptide- spiked plasma sample/sample ratio

Additional outcomes, including the pathological complete response (pCR), were studied in a retrospective analysis of 347 patients with earlystage triplenegative breast cancer (TNBC) who received KEYNOTE522 and GLP1 RAs or DPP4i treatment at diagnosis and throughout the neoadjuvant period

Updated Schedule: ADA Boot Camp, Tech, MNT & More Live in Beautiful San Diego Oct 22-23, 2026 Re-Ignite your Passion & Prepare for Diabetes Certification Exams Earn 30+ CEs: AMA PRA Category 1 Credits , ACPE, ANCC, and CDR